Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of California Davis Comprehensive Cancer Center

I typically do not give enasidenib with azacitidine upfront for patients with AML with IDH2 mutation and ineligible for intensive induction chemotherapy. Based on the results of the VIALE-A study (DiNardo et al, NEJM 2020), I usually give venetoclax with azacitidine to those patients. In addition to...

Which neoadjuvant/adjuvant chemotherapy regimen would you select in a patient with resectable stage IB pancreatic head adenocarcinoma and MDS-SF3B1 on luspatercept (baseline Hgb of 8-9 g/dL)?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

Seems a bit unfair that the patient has both! First, I would consider resection upfront to ensure this key step rather than risk additional complications of chemotherapy. Perioperative or total neoadjuvant therapy is not standard for resectable disease yet (pending Alliance trial result). Second, bo...

When consolidating DLBCL with radiotherapy, do you treat all originally involved sites, or just initially bulky and partial responder sites?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University Hospital Basel

When consolidating DLBCL with radiotherapy, several parameters must be taken into consideration. a) Is radiation therapy part of the treatment plan "on top" of full systemic treatment because of a certain risk situation due to not-optimal response of disease to systemic treatment (for example, FDG-a...

Is enteric-coated aspirin acceptable to use in polycythemia vera or ET?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Virginia Mason Medical Center

Admittedly, this is a question I had not considered before viewing this query, as I rarely, if ever, prescribe enteric-coated aspirin. In the absence of a bleeding diathesis such as von Willebrand disease, platelet count greater than one million/mm³, or active GI bleeding, low-dose aspirin (75/81/10...

What is your preferred 1L treatment for newly diagnosed Del(17p)/TP53 mutation, high-risk CLL?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · MD Anderson Cancer Center Hospital

For patients with TN-CLL with TP53 aberration, the treatment options are usually based on patient factors. If a patient is a candidate for combination therapy, I prefer to treat them with uMRD-guided BTKi+BCL2i ± CD20 mAb. I only add a CD20 mAb to patients with no history of frequent infections and ...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

What is your preferred first-line therapy for transfusion-dependent beta-thalassemia?

1
1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

Transfusion is my preferred first-line therapy (and standard of care) for beta-thalassemia major. For beta-thalassemia intermedia that has evolved into TDT, my preferred first-line treatment is mitapivat over luspatercept, particularly if the patient has extramedullary masses (that have been noted t...

Are there still clinical situations in which you deliberately treat patients with a DOAC besides apixaban?

2
6 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of Chicago

Thank you for your question. Apixaban has been my preferred agent for a long time for patients requiring therapeutic anticoagulation. Apixaban’s lower bleeding risk was shown prior to and now has additional evidence to support this with the COBRRA trial. The risk is also ameliorated by the safety in...

Would you consider perioperative antifibrinolytics for mild factor 7 deficiency undergoing surgery?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh Medical Center

I do use antifibrinolytics in factor VII deficiency; however, it depends on the specifics of the surgery (i.e., mucosal surface surgery, sequelae of bleeding should it occur - spine vs oral), the patient's bleeding history, and the factor VII level. Here, I wonder if the original diagnosis was corre...